Skip to main content

Oncolytic Virus Therapies Market is projected to grow at a whopping CAGR of 26.28% over the period 2020-2030

 The global oncolytic virus therapies market is undergoing a significant flux with regard to the advancements that have already taken place and are currently invading the market space. Additionally, with the emergence of virus therapeutics, there is an immense potential for these emerging sub-markets to continue fueling the overall oncolytic virus therapies market. This chapter reviews the significant drivers and restraints that are considerably impacting the dynamicity of the global oncolytic virus therapies market.

Due to the ever-rising incidence of cancers, the need for better products and services is becoming more evident. Several key players are aligning their technologies as per the market requirements to provide technologically advanced products and services by adopting inorganic strategies such as agreements, partnerships, and collaborations.

The global oncolytic virus therapies market is projected to grow at a whopping CAGR of 26.28% over the period 2020-2030 and reach a market value of $962 million by 2030. 



The challenges associated with the global oncolytic virus therapies market are High cost of therapy and lack of therapy-specific-assays may cause hindrance in the adoption of oncolytic virus therapies globally. In 2020, the North American region held the largest share in the global market for oncolytic virus therapies owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region.


Market Segmentation

•    Commercialized Therapies: Imlygic, Oncorine, and RIGVIR

•    Pipeline Therapies: Phase I, Phase II, Phase III

•    Type of Virus: Genetically Engineered Oncolytic Viruses (Herpes Simplex Virus, Adenovirus, and Vaccinia Virus), Oncolytic Wild Type Viruses (Reovirus, Newcastle Disease Virus, and Vesicular Stomatitis Virus)

•    Application: Solid Tumors (Breast Cancer, Prostate Cancer, Lung Cancer, Glioblastoma, and Melanoma), Hematological Malignancies (Lymphoma, Leukemia, and Myeloma)


Regional Segmentation

•    North America: U.S.

•    Europe: Germany, France, Italy, U.K., Latvia, Armenia, Georgia, Rest-of-the-Europe (Spain, Russia, Switzerland)

•    Asia-Pacific – Japan, China, Rest-of-APAC (India, Australia, South Korea)


Growth Drivers

•    Increasing Incidence of Cancer

•    Rising Number of Clinical Trials

•    Increasing Research Funding from National Cancer Institute

•    Increasing Adoption of Inorganic Growth Strategies in the Market


Market Restraints

•    High Cost of Therapy

•    Lack of Therapy-Specific Assays


Market Opportunities

•    Opportunities in the Emerging Economies

•    Drug Approvals and Strong Pipeline of Oncolytic Virus Therapies


Key Companies Profiled

Amgen, Inc., DAIICHI SANKYO COMPANY, LIMITED, DNAtrix, Genelux, Oncolytics Biotech, Inc., PsiOxus Therapeutics, RIGVIR Ltd., Shanghai Sunway Biotech Co., Ltd., SillaJen, Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., Transgene sa, VCN Biosciences, ViroCure, Viralytics Ltd.


Request a Sample- https://bisresearch.com/requestsample?id=1099&type=download

Labels:

Comments

Post a Comment

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...
Post a Comment
Read more

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

  The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global  ligase market  is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development.   Impact Several techniques are employed in ...
Post a Comment
Read more

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

  PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market   are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...
Post a Comment
Read more